Key Takeaways
- Starting dose: 2.5mg once weekly for the first 4 weeks
- Maintenance dose: 5mg, 10mg, or 15mg weekly depending on response
- Titration schedule: Increase every 4 weeks: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg
- Half-life: Approximately 5 days, supporting once-weekly dosing
- Clinical efficacy: SURMOUNT-1 showed up to 20.9% average weight loss at 72 weeks
✓ FDA-Approved: Tirzepatide is FDA-approved as Zepbound (for weight management) and Mounjaro (for type 2 diabetes). Both brands contain the same molecule and follow the same dosing protocol.
Dual GLP-1/GIP mechanism: enhanced appetite suppression and metabolic benefits
Tirzepatide Dosing Schedule Overview
Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP receptor agonist. In SURMOUNT-1, participants on the highest dose (15mg) lost an average of 20.9% of body weight over 72 weeks, numbers that previously required bariatric surgery.
The tirzepatide dosing protocol involves a gradual titration over 20+ weeks. Unlike semaglutide which has a single maintenance dose (2.4mg), tirzepatide offers three maintenance dose options (5mg, 10mg, 15mg), allowing for individualized treatment based on response and tolerability.
📋 Brand Information: Zepbound is for chronic weight management. Mounjaro is for type 2 diabetes. Same medication, same doses, different indications. Compounded tirzepatide follows the same protocol.
Standard Titration Schedule (FDA Protocol)
| Phase | Weeks | Weekly Dose | Purpose |
|---|---|---|---|
| Initial | 1-4 | 2.5mg | GI adaptation phase |
| Maintenance 1 | 5-8 | 5mg | First maintenance option |
| Escalation | 9-12 | 7.5mg | Transitional dose |
| Maintenance 2 | 13-16 | 10mg | Second maintenance option |
| Escalation | 17-20 | 12.5mg | Transitional dose |
| Maintenance 3 | 21+ | 15mg | Maximum dose (optional) |
Important: Unlike semaglutide, tirzepatide has multiple maintenance doses. You can stay at 5mg, 10mg, or 15mg long-term. There's no requirement to reach the maximum dose. Choose based on your individual response and tolerability.
Use our free tirzepatide dosing calculator to visualize your specific protocol and see projected drug levels over time.
Understanding Tirzepatide: Mechanism and Pharmacology
What it is: Tirzepatide is the first FDA-approved dual GLP-1/GIP receptor agonist. Unlike semaglutide which only activates GLP-1 receptors, tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual action produces greater weight loss and metabolic improvements than GLP-1 alone.
Dual-Agonist Mechanism of Action
GLP-1 Pathway (Glucagon-Like Peptide-1)
Acts on hypothalamic receptors to suppress appetite and increase satiety. Stimulates insulin secretion in a glucose-dependent manner and slows gastric emptying, so you feel full longer after meals. May also reduce food reward signaling and cravings. This is the same pathway that semaglutide and other GLP-1 agonists target.
GIP Pathway (Glucose-Dependent Insulinotropic Polypeptide)
GIP is the second incretin hormone, historically less studied than GLP-1. GIP receptors sit in pancreatic beta cells (where they boost insulin secretion), adipose tissue (where they may influence fat metabolism and distribution), and the central nervous system (where they may play a role in appetite regulation). Adding GIP activation on top of GLP-1 appears to amplify metabolic effects beyond what GLP-1 alone can do.
Synergistic Effect
In head-to-head trials (SURPASS-2), tirzepatide produced significantly more weight loss and HbA1c reduction than semaglutide alone. The GIP component likely improves insulin sensitivity and fat oxidation through pathways distinct from GLP-1, which helps explain the stronger results.
Pharmacokinetics: Half-Life and Steady State
Half-life: Tirzepatide has a half-life of approximately 5 days, which supports once-weekly dosing. Drug levels peak around 8-72 hours after injection and then gradually decline.
Steady state: It takes approximately 4-5 weeks of consistent weekly dosing for tirzepatide to reach steady-state concentration. This is why each dose level should be maintained for at least 4 weeks before increasing.
Shorter half-life implications: With a 5-day half-life (vs semaglutide's 7 days), tirzepatide levels fluctuate slightly more during the week. Some users report appetite returning toward the end of the week. This is one reason some explore split dosing strategies. For a deeper look at how half-life governs steady-state accumulation and concentration curves, see our pharmacokinetics guide.
📊 Visualization: Our pharmacokinetics calculator shows your projected drug levels over time, including the peak-to-trough variation during each week.
Clinical Trial Data: SURMOUNT and SURPASS Programs
Tirzepatide was studied in two major trial programs: SURPASS (diabetes) and SURMOUNT (obesity). The results established tirzepatide as the most effective approved anti-obesity medication.
SURMOUNT-1: Primary Obesity Trial
2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related complications, without diabetes, randomized to tirzepatide 5mg, 10mg, or 15mg versus placebo for 72 weeks.
| Measure | 5mg | 10mg | 15mg | Placebo |
|---|---|---|---|---|
| Mean weight loss | 15.0% | 19.5% | 20.9% | 3.1% |
| ≥5% weight loss | 85% | 89% | 91% | 35% |
| ≥10% weight loss | 69% | 79% | 84% | 19% |
| ≥20% weight loss | 32% | 50% | 57% | 3% |
Source: Jastreboff et al., NEJM 2022
SURPASS-2: Head-to-Head vs Semaglutide
1,879 adults with type 2 diabetes randomized to tirzepatide 5mg, 10mg, or 15mg versus semaglutide 1mg for 40 weeks.
- HbA1c reduction: Tirzepatide 15mg: -2.30% vs Semaglutide 1mg: -1.86%
- Additional weight loss vs semaglutide: 5mg: -1.9 kg more, 10mg: -3.6 kg more, 15mg: -5.5 kg more
- Primary endpoint: All tirzepatide doses were noninferior AND superior to semaglutide
Source: Frías et al., NEJM 2021
SURMOUNT-2: Obesity with Type 2 Diabetes
938 adults with obesity AND type 2 diabetes randomized to tirzepatide 10mg, 15mg, or placebo for 72 weeks.
- 10mg weight loss: 12.8%
- 15mg weight loss: 14.7%
- Placebo: 3.2%
Note: Weight loss in diabetes populations is typically lower than in non-diabetic populations due to insulin's effects on fat storage.
SURMOUNT-4: Maintenance Study
A randomized withdrawal trial showing the importance of continued treatment: participants who switched from tirzepatide to placebo after 36 weeks regained most of their lost weight, while those continuing tirzepatide maintained or continued losing weight.
Key finding: Tirzepatide suppresses the biological drivers of obesity while you take it. Stop, and those drivers come back.
Watch: Understanding Tirzepatide
These videos explain tirzepatide's dual mechanism and clinical evidence from authoritative sources.
NEJM: Official SURMOUNT-1 trial summary (111K views)
Dr. McGowan: Tirzepatide vs Semaglutide comparison (188K views)
Starting Dose for Tirzepatide
The recommended tirzepatide starting dose is 2.5mg once weekly. This is a sub-therapeutic dose designed solely for GI adaptation. Don't expect significant weight loss at this dose.
Why Start at 2.5mg?
- Dual receptor adaptation: Both GLP-1 and GIP pathways need gradual introduction
- GI tolerability: Your gut needs time to adjust to slowed gastric emptying
- Nausea prevention: Starting higher dramatically increases nausea and vomiting rates
- Dropout reduction: Gradual titration keeps more people on treatment long-term
What to Expect at 2.5mg
At the starting dose, you may notice:
- Mild appetite reduction (variable; some feel nothing at this dose)
- Subtle feeling of fullness after meals
- Possible mild nausea, especially with large or fatty meals
- Minor injection site reactions
Important: The 2.5mg dose is for tolerability, not results. Weight loss typically becomes meaningful at 5mg and increases substantially at 10mg and 15mg. Be patient with the titration process.
Tirzepatide Titration Schedule
The tirzepatide titration schedule follows a 4-week escalation pattern. For a quick visual reference, see our printable tirzepatide dosage chart. The key difference from semaglutide is the multiple maintenance dose options, and you choose where to stay based on your response.
Week-by-Week Breakdown
Weeks 1-4: 2.5mg/week (Initiation)
Establish your injection routine. Pick a consistent day each week. Monitor for side effects but don't expect dramatic changes. This dose is sub-therapeutic by design.
Weeks 5-8: 5mg/week (Maintenance Option 1)
First therapeutic dose. Appetite suppression becomes noticeable. Some GI side effects may emerge. In SURMOUNT-1, even 5mg achieved 15% average weight loss at 72 weeks. Many patients can achieve excellent results at this dose with good tolerability.
Weeks 9-12: 7.5mg/week (Transition)
Intermediate dose between maintenance options. Appetite suppression strengthens. If 5mg provided good results with manageable side effects, consider staying there instead of continuing up.
Weeks 13-16: 10mg/week (Maintenance Option 2)
Second therapeutic dose option. Significant weight loss typically occurs. SURMOUNT-1 showed 19.5% average weight loss at this dose. This is often the "sweet spot" balancing efficacy and tolerability.
Weeks 17-20: 12.5mg/week (Transition)
Intermediate dose toward maximum. Only continue if you want/need more effect and 10mg is well-tolerated. Side effects may increase.
Weeks 21+: 15mg/week (Maintenance Option 3 - Maximum)
Maximum approved dose. Strongest appetite suppression and weight loss (20.9% average in SURMOUNT-1). Not everyone needs or tolerates this dose. 57% of participants reached ≥20% weight loss at 15mg vs 50% at 10mg. The incremental benefit may not be worth increased side effects for everyone.
Choosing Your Maintenance Dose
Consider staying at a lower maintenance dose if:
- You're achieving satisfactory weight loss at 5mg or 10mg
- Side effects are well-controlled at your current dose
- You prefer the milder appetite suppression (extreme food aversion can impact quality of life)
- Cost considerations (higher doses = more medication per week)
Consider continuing to 15mg if:
- You have significant weight to lose and want maximum efficacy
- Lower doses provided insufficient appetite suppression
- Side effects at 10mg are manageable
- You're tolerating the medication well overall
Managing Tirzepatide Side Effects
Most tirzepatide side effects are gastrointestinal and typically improve with time. In SURMOUNT-1, nausea occurred in 24-33% of participants (vs 10% placebo), but most cases were mild-to-moderate and occurred during dose escalation.
Side Effects by Dose (SURMOUNT-1 Data)
| Side Effect | 5mg | 10mg | 15mg | Placebo |
|---|---|---|---|---|
| Nausea | 24% | 27% | 33% | 10% |
| Diarrhea | 19% | 21% | 23% | 7% |
| Constipation | 16% | 17% | 17% | 5% |
| Vomiting | 8% | 10% | 12% | 2% |
| Discontinuation due to AE | 4.3% | 7.1% | 6.2% | 2.6% |
Management Strategies
Nausea
- Eat smaller, more frequent meals
- Avoid fatty, greasy, or spicy foods, especially early in treatment
- Stop eating at the first sign of fullness
- Ginger tea, ginger supplements, or ginger candies
- Stay well-hydrated, as dehydration worsens nausea
- Consider slower titration if persistent
Constipation
- Increase fiber intake gradually (vegetables, fruits, whole grains)
- Drink plenty of water; aim for 64+ oz daily
- Consider a fiber supplement (psyllium husk)
- Magnesium citrate or glycinate may help
- Regular physical activity promotes gut motility
Diarrhea
- Avoid high-fat foods which can worsen symptoms
- Limit caffeine and artificial sweeteners
- Stay hydrated and replace lost fluids and electrolytes
- Usually improves as body adapts to medication
"Sulfur Burps" (Eructation)
- Somewhat unique to tirzepatide: sulfur-smelling belching
- Avoid high-sulfur foods (eggs, cruciferous vegetables, garlic)
- Eat slowly and avoid carbonated beverages
- Smaller, more frequent meals may help
- Often improves with time as GI tract adapts
When to Seek Medical Attention
Contact a healthcare provider immediately if you experience:
- Severe abdominal pain that doesn't go away
- Symptoms of pancreatitis (severe upper abdominal pain radiating to back)
- Signs of allergic reaction (swelling, difficulty breathing, severe rash)
- Persistent vomiting leading to dehydration
- Symptoms of hypoglycemia (if on sulfonylurea or insulin)
Contraindications, Warnings, and Who Should Not Use Tirzepatide
⚠️ Black Box Warning: Thyroid C-Cell Tumors
In rodent studies, tirzepatide caused thyroid C-cell tumors. Whether this translates to humans is unknown. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Routine thyroid monitoring does not detect this risk and is not recommended as a screening measure.
Who Should Not Take Tirzepatide
- Personal or family history of medullary thyroid carcinoma (MTC): absolute contraindication
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): absolute contraindication
- Serious hypersensitivity to tirzepatide or any component of the formulation
- History of pancreatitis: tirzepatide has not been studied in this population; discuss with your prescriber before use
Pregnancy and Breastfeeding
Pregnancy: Tirzepatide is not recommended during pregnancy. Animal studies found higher rates of fetal malformations. Data in human pregnancies are insufficient to assess risk properly. If you become pregnant while on tirzepatide, contact your doctor.
Oral contraceptive effectiveness: Tirzepatide slows gastric emptying, which can reduce oral contraceptive absorption. Eli Lilly recommends using a barrier method or non-oral contraception for at least 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. After that window, oral contraceptives generally maintain adequate efficacy.
Breastfeeding: No data exist on tirzepatide in human milk. Due to potential risk to nursing infants, tirzepatide is not recommended while breastfeeding.
Kidney and Liver Impairment
No dose adjustment is required for renal or hepatic impairment. That said, GI side effects (nausea, vomiting, diarrhea) can cause dehydration, which puts added strain on the kidneys. Stay well hydrated, particularly during the titration phase, and flag persistent GI symptoms to your prescriber.
Tirzepatide Drug Interactions
Tirzepatide has no direct pharmacokinetic drug-drug interactions, but slowed gastric emptying affects how quickly your body absorbs other medications. A few specific interactions are worth knowing before you start.
Oral Contraceptives
The most clinically relevant interaction. Slowed gastric emptying reduces oral contraceptive absorption. Use a barrier method or switch to non-oral contraception for at least 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. After that adjustment window, the effect on absorption stabilizes and most oral contraceptives maintain adequate efficacy.
Insulin and Sulfonylureas
Tirzepatide does not cause hypoglycemia on its own. But if you take insulin or a sulfonylurea (like glipizide or glimepiride) alongside tirzepatide, the combined glucose-lowering effect can push blood sugar too low. Your prescriber may reduce the insulin or sulfonylurea dose when you start tirzepatide. Monitor blood glucose more closely during the titration phase.
Other Oral Medications
For drugs where precise absorption timing matters (some antibiotics, thyroid medications, narrow therapeutic index drugs), flag this to your prescriber before starting tirzepatide. In most cases no action is needed, but it is worth discussing if you are on multiple oral medications with strict timing requirements.
Mounjaro vs Zepbound: Understanding the Difference
Mounjaro and Zepbound contain the exact same active ingredient (tirzepatide) at the same doses. The only difference is the FDA-approved indication and pricing.
| Feature | Mounjaro | Zepbound |
|---|---|---|
| FDA Indication | Type 2 Diabetes | Chronic Weight Management |
| Available Doses | 2.5, 5, 7.5, 10, 12.5, 15mg | 2.5, 5, 7.5, 10, 12.5, 15mg |
| Active Ingredient | Tirzepatide | Tirzepatide (identical) |
| Manufacturer | Eli Lilly | Eli Lilly |
| Insurance Coverage | Often covered with diabetes diagnosis | Rarely covered (obesity) |
Practical tip: If you have type 2 diabetes in addition to obesity, you may find Mounjaro more accessible through insurance. The weight loss effect is identical; it's the same medication.
Tirzepatide for Sleep Apnea: The 2024 FDA Approval
In late 2024, the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, making it the first prescription medication approved specifically for this condition. The approval was based on two phase 3 SURMOUNT-OSA trials.
SURMOUNT-OSA Trial Results
738 adults with obesity and moderate-to-severe OSA (apnea-hypopnea index ≥15 events/hour) across two trials: one in participants not using PAP therapy, one in PAP users.
- AHI reduction: Tirzepatide 15mg reduced apnea-hypopnea events by approximately 25-30 per hour vs 5 per hour for placebo
- Responder rate: Around 42% of tirzepatide participants achieved complete or near-complete resolution of sleep apnea events
- Weight loss: Average 18% body weight reduction accompanied the AHI improvements, consistent with SURMOUNT-1 data at comparable doses
Source: Malhotra et al., NEJM 2024
Sleep Apnea Dosing vs Weight Loss Dosing
The titration schedule is the same for both indications. The difference is in the maintenance dose: 5mg is approved for weight loss maintenance but not for sleep apnea.
| Indication | Approved Maintenance Doses | Lowest Approved Maintenance |
|---|---|---|
| Weight loss | 5mg, 10mg, or 15mg | 5mg |
| Sleep apnea (OSA) | 10mg or 15mg | 10mg (5mg not approved for OSA) |
How it works: Tirzepatide reduces sleep apnea primarily through weight loss rather than direct action on upper airway muscles or breathing control. Losing significant body weight reduces the fat deposits around the throat that obstruct the airway during sleep. If you stop tirzepatide and regain the weight, OSA symptoms typically return.
Compounded Tirzepatide Considerations
Due to brand-name costs and availability issues, many people obtain compounded tirzepatide from 503A or 503B compounding pharmacies. For a full breakdown of tirzepatide pricing options, including LillyDirect self-pay vials and savings cards; see our tirzepatide cost guide. Here's what to know:
Dosing with Compounded Formulations
- Same titration applies: Follow the standard FDA protocol regardless of source
- Know your concentration: Compounded tirzepatide comes in various concentrations (e.g., 5mg/mL, 10mg/mL)
- Use a calculator: Our tool helps you determine the correct syringe volume for any concentration
- Verify quality: Request certificate of analysis (CoA) from your pharmacy
💡 Calculator tip: Enter your vial concentration into our tirzepatide calculator to see exactly how many units to draw for each dose. No more math errors.
→ For complete details on compounded options, see our compounded tirzepatide guide covering sourcing, quality considerations, pricing, and safety.
Common Compounded Concentrations
| Concentration | 2.5mg Dose | 5mg Dose | 10mg Dose | 15mg Dose |
|---|---|---|---|---|
| 5mg/mL | 50 units | 100 units | 200 units* | 300 units* |
| 10mg/mL | 25 units | 50 units | 100 units | 150 units* |
| 20mg/mL | 12.5 units | 25 units | 50 units | 75 units |
*Exceeds standard 100-unit syringe. May need larger syringe or split injection. Based on 100-unit insulin syringe (1 unit = 0.01 mL).
Tirzepatide vs Semaglutide: Which is Better?
Both are excellent medications. Tirzepatide has demonstrated greater efficacy in head-to-head trials, but semaglutide has more long-term safety data. Here's how they compare:
| Factor | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | Dual GLP-1/GIP agonist | GLP-1 agonist only |
| Average Weight Loss | Up to 20.9% | Up to 14.9% |
| Half-Life | ~5 days | ~7 days |
| Dose Flexibility | 3 maintenance options | 1 target dose |
| CV Outcomes Data | Ongoing (SURPASS-CVOT) | Yes (SELECT trial) |
| Years on Market | Since 2022 | Since 2017 |
Bottom line: Tirzepatide produces more weight loss in clinical trials. Semaglutide has proven cardiovascular benefits and longer safety track record. Both are reasonable choices. Discuss with your healthcare provider based on your specific situation.
Tirzepatide Best Practices
Injection Technique
- Inject subcutaneously: Abdomen (2+ inches from navel), front of thighs, or upper arms
- Rotate sites: Don't inject in the same spot twice in a row
- Same day each week: Pick a consistent day; time of day doesn't matter
- With or without food: Tirzepatide can be taken regardless of meals
- Room temperature: Cold medication stings more, so let it warm up slightly
Lifestyle Optimization
- Prioritize protein: Aim for 25-30g protein per meal to preserve muscle mass
- Resistance training: Weight loss includes muscle, so strength training helps maintain it
- Hydration: 64+ oz water daily; more if exercising or experiencing diarrhea
- Monitor vitamins: Reduced food intake may impact B12, iron, and other nutrients
Missed Dose Protocol
- Within 4 days of scheduled dose: Take it as soon as you remember, then resume normal schedule
- More than 4 days late: Skip the missed dose and take the next one on schedule
- Never double up: Don't take two doses to make up for a missed one
Frequently Asked Questions
How long does it take for tirzepatide to work?
Most people notice appetite changes within the first 1-2 weeks, even at the 2.5mg starting dose. However, meaningful weight loss typically begins at the 5mg dose and increases substantially at 10mg and 15mg. In clinical trials, weight loss continued through 72 weeks.
Do I need to reach 15mg for best results?
No. Unlike semaglutide which has one target dose, tirzepatide offers three maintenance options. Many patients achieve excellent results at 5mg or 10mg with better tolerability. The 15mg dose provides incrementally more weight loss but with more side effects. Choose based on your response.
Why do I feel hungry at the end of the week?
Tirzepatide has a shorter half-life (~5 days) compared to semaglutide (~7 days), so drug levels drop more noticeably toward day 7. Some users explore split dosing strategies to smooth out this variation, though this is off-label.
What happens if I stop taking tirzepatide?
The SURMOUNT-4 trial showed that participants who stopped tirzepatide regained most of their lost weight within a year, while those who continued maintained their weight loss. This is because tirzepatide addresses the biological drivers of obesity while you take it.
Can I switch from semaglutide to tirzepatide?
Yes, switching is possible and increasingly common. However, there's no official guidance on dose equivalence. A conservative approach is to restart tirzepatide at 2.5mg for GI adaptation to the new medication, though some providers start higher based on the prior semaglutide dose.
What are the "sulfur burps" and how do I stop them?
Eructation (sulfur-smelling belching) is more common with tirzepatide than semaglutide. It's related to slowed gastric emptying and gut motility changes. Avoiding high-sulfur foods (eggs, cruciferous vegetables), eating slowly, avoiding carbonated drinks, and eating smaller meals can help. It often improves with time.
Does tirzepatide affect oral birth control?
Yes. Tirzepatide slows gastric emptying, which can reduce how much oral contraceptive your body absorbs. Eli Lilly recommends using a barrier method or switching to non-oral contraception for at least 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. After that adjustment window, oral contraceptives generally maintain adequate efficacy.
Is tirzepatide approved for sleep apnea?
Yes. In late 2024, the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity. The sleep apnea maintenance dose is 10mg or 15mg weekly. The 5mg maintenance dose is not approved for this indication. Tirzepatide works primarily by reducing body weight, which in turn reduces airway obstruction.
Can tirzepatide cause thyroid cancer?
Tirzepatide carries an FDA black box warning based on rodent studies showing thyroid C-cell tumors. Whether this occurs in humans is unknown. Tirzepatide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Routine thyroid monitoring does not screen for this risk. If you have no personal or family history of these conditions, the current evidence does not indicate a significant human risk.
Plan Your Tirzepatide Protocol
Our free pharmacokinetics calculator shows your projected drug levels, helps you calculate syringe volumes for compounded medication, and lets you visualize different titration schedules.
Open Tirzepatide CalculatorRelated Articles
How to Reconstitute Tirzepatide
Step-by-step guide with calculator for compounded peptides
Tirzepatide Microdosing Guide
Split dosing strategies for improved tolerability
Retatrutide vs Tirzepatide
Dual vs triple agonist comparison
Semaglutide Dosing Guide
Complete guide to the GLP-1 alternative
Tirzepatide Resource Hub
All tirzepatide guides and tools
Medical Disclaimer: This guide is for informational purposes only and does not constitute medical advice. Tirzepatide is a prescription medication that should only be used under the supervision of a qualified healthcare provider. Individual results vary. Always consult your doctor before starting, changing, or stopping any medication.